The opinion will now be referred to the European Commission for final regulatory decision on donanemab  INDIANAPOLIS, July 25 ...

The opinion is based on positive data from the phase 3 Balance study, which showed a significant reduction of triglycerides ...

The drug failed to meet its primary endpoints in clinical trials, but subgroup analyses hinted at modest benefits.

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Gilead ...

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 January 2014 By Emily Wasserman Jan 24, 2014 7:35am Pharma ...

The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease PR Newswire TOKYO and CAMBRIDGE, Mass., Feb. 28, 2025 ...

Committee for Medicinal Products for Human Use Summary of Positive Opinion for Optaflu LONDON, April 26, 2007-On 26 April 2007 the Committee for Medicinal Products for Human Use (CHMP) adopted a ...

LONDON, Oct. 23, 2008-On 23 October 2008 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion** to recommend the variation to the terms of the marketing ...

By Eric PalmerSep 20, 2013 8:51am Pharma Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP), 16-19 September 2013 ...

STOCKHOLM, Feb. 28, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that the Committee for Medicinal Products for Human Use (CHMP) of the ...

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: development of the Company’s ...